HAVCR2
protein-codinghepatitis A virus cellular receptor 2, the group of V-set domain containing
Gene summary
The protein encoded by this gene belongs to the immunoglobulin superfamily, and TIM family of proteins. CD4-positive T helper lymphocytes can be divided into types 1 (Th1) and 2 (Th2) on the basis of their cytokine secretion patterns. Th1 cells are involved in cell-mediated immunity to intracellular pathogens and delayed-type hypersensitivity reactions, whereas, Th2 cells are involved in the control of extracellular helminthic infections and the promotion of atopic and allergic diseases. This protein is a Th1-specific cell surface protein that regulates macrophage activation, and inhibits Th1-mediated auto- and alloimmune responses, and promotes immunological tolerance. [provided by RefSeq, Sep 2011]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~57.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0019475
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:1060169
Submitter: ClinGen
HAVCR2 was first reported in relation to autosomal recessive HAVCR2- related subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and/or hemophagocytic lymphohistiocytosis (HLH) predisposition in 2018 (Gayden et al., PMID: 30374066). Affected individuals typically present with multiple subcutaneous nodules and systemic B-cell symptoms. SPTCL can follow a fulminant course when associated with hemophagocytic lymphohistiocytosis (HLH), which accompanies ~20% of cases and decreases 5 year survival from 90% to less than 50%. As there is a spectrum of SPTCL and HLH outcomes that are considered under one disease assertion, HAVCR2-related SPTCL and/or HLH predisposition, no lumping and splitting was needed for this curation. Five missense variants that have been reported in 37 probands in 8 publications (PMIDs: 30792187, 37062931, 38077348, 30374066, 36212426, 34398459, 34398505, 32285995) are included in this curation. There was a range of different phenotypic manifestations, from isolated SPTCL, to isolated HLH, with some cases reported with both SPTCL and HLH. This gene-disease association is also supported by expression and functional studies (PMIDs: 30374066, 32285995). These experiments indicate that HAVCR2 variants lead to reduced Tim-3 expression and can cause an increased inflammatory response. In summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. This classification was approved by the ClinGen Childhood, Adolescent, and Young Adult Cancer Predisposition GCEP on the meeting date June 10, 2025 (SOP Version 11).
Inheritance Pattern: AR
Disease ID:MONDO:0019475
Submitter: G2P
Clinical Genomic Database (CGD)
Manifestation: Oncologic
Intervention: Oncologic
Rationale: Individuals have been described as being susceptible to form of T-cell non-Hodgkin lymphoma, and awareness may allow early surveillance, diagnosis, and management (immunosuppressive and chemotherapeutic treatment has been reported as effective); HSCT has been reported as curative
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to HAVCR2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_032782.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 12 | 12 | ||||
| missense | 1 | 44 | 15 | 60 | ||
| nonsense | 1 | 1 | ||||
| start loss | 0 | |||||
| frameshift | 2 | 2 | ||||
| splice donor/acceptor (+/-2bp) | 2 | 2 | ||||
| Total | 0 | 1 | 49 | 27 | 0 | 77 |
Highest pathogenic variant AF is 0.000040891333
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_116171.3 | 7 | MANE Select | |
| Ensembl | ENSP00000312002.4 | 7 | MANE Select | |
| Ensembl | ENSP00000513313.1 | 6 | Standard | |
| Ensembl | ENSP00000513313.1 | 6 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Ebola Virus Pathway on Host
- Ebola Virus Pathway on Host
- Signaling by Interleukins
- Cytokine Signaling in Immune system
- Immune System
Biological Process
- adaptive immune response
- macrophage activation involved in immune response
- natural killer cell tolerance induction
- regulation of tolerance induction dependent upon immune response
- negative regulation of T-helper 1 type immune response
Molecular Function
- protein binding
- metal ion binding
Cellular Component
- immunological synapse
- early endosome
- cell surface
- integral component of membrane
- mediator complex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000307851
- Coding exons
- 7
- Length
- 57038
- Individuals with no LoFs
- 125672
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 3
- Defined
- 125675
- p
- 0.0000119
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.635 | 147 | 170 | 0.863 | 0.00000927 | 1925 |
| Missense (PolyPhen) | 25 | 39.508 | 0.63279 | 455 | ||
| Synonymous | 0.401 | 64 | 68.2 | 0.938 | 0.00000381 | 613 |
| Loss of Function | 1.89 | 4 | 10.7 | 0.375 | 4.49e-7 | 139 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000028 | 0.000026 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Cell surface receptor implicated in modulating innate and adaptive immune responses. Generally accepted to have an inhibiting function. Reports on stimulating functions suggest that the activity may be influenced by the cellular context and/or the respective ligand (PubMed:24825777). Regulates macrophage activation (PubMed:11823861). Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance (PubMed:14556005). In CD8+ cells attenuates TCR-induced signaling, specifically by blocking NF- kappaB and NFAT promoter activities resulting in the loss of IL-2 secretion. The function may implicate its association with LCK proposed to impair phosphorylation of TCR subunits, and/or LGALS9- dependent recruitment of PTPRC to the immunological synapse (PubMed:24337741, PubMed:26492563). In contrast, shown to activate TCR-induced signaling in T-cells probably implicating ZAP70, LCP2, LCK and FYN (By similarity). Expressed on Treg cells can inhibit Th17 cell responses (PubMed:24838857). Receptor for LGALS9 (PubMed:16286920, PubMed:24337741). Binding to LGALS9 is believed to result in suppression of T-cell responses; the resulting apoptosis of antigen-specific cells may implicate HAVCR2 phosphorylation and disruption of its association with BAG6. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens. Expressed on Th1 cells interacts with LGALS9 expressed on Mycobacterium tuberculosis- infected macrophages to stimulate antibactericidal activity including IL-1 beta secretion and to restrict intracellular bacterial growth (By similarity). However, the function as receptor for LGALS9 has been challenged (PubMed:23555261). Also reported to enhance CD8+ T-cell responses to an acute infection such as by Listeria monocytogenes (By similarity). Receptor for phosphatidylserine (PtSer); PtSer-binding is calcium-dependent. May recognize PtSer on apoptotic cells leading to their phagocytosis. Mediates the engulfment of apoptotic cells by dendritic cells. Expressed on T-cells, promotes conjugation but not engulfment of apoptotic cells. Expressed on dendritic cells (DCs) positively regulates innate immune response and in synergy with Toll-like receptors promotes secretion of TNF-alpha. In tumor-imfiltrating DCs suppresses nucleic acid-mediated innate immune repsonse by interaction with HMGB1 and interfering with nucleic acid-sensing and trafficking of nucleid acids to endosomes (By similarity). Expressed on natural killer (NK) cells acts as a coreceptor to enhance IFN-gamma production in response to LGALS9 (PubMed:22323453). In contrast, shown to suppress NK cell-mediated cytotoxicity (PubMed:22383801). Negatively regulates NK cell function in LPS-induced endotoxic shock (By similarity). {ECO:0000250|UniProtKB:Q8VIM0, ECO:0000269|PubMed:11823861, ECO:0000269|PubMed:14556005, ECO:0000269|PubMed:16286920, ECO:0000269|PubMed:22323453, ECO:0000269|PubMed:23555261, ECO:0000269|PubMed:24838857, ECO:0000269|PubMed:26492563, ECO:0000305|PubMed:24825777}.;
- Disease
- DISEASE: Note=May be involved in T-cell exhaustion associated with chronic viral infections such as with human immunodeficiency virus (HIV) and hepatitic C virus (HCV). {ECO:0000269|PubMed:19001139, ECO:0000269|PubMed:19587053}.;
Intolerance Scores
- LoFtool
- 0.713
- RVIS EVS
- 0.97
- RVIS percentile EVS
- 90.34
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.331
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |